Protooncogene bcl-2 gene transfer abrogates Fas/APO-1 antibody-mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation

Journal of Clinical Investigation

Volumn 95, Issue 6, 1995, Pages 2633-2643

  Weller, Michael ^a,c   Malipiero, Ursula ^a   Aguzzi, Adriano ^a   Reed, John C ^b   Fontana, Adriano ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b BURNHAM INSTITUTE   (United States)

^c UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

brain tumor; CD95; glioblastoma; immunotherapy; programmed cell death

Indexed keywords

ANTINEOPLASTIC AGENT; CARMUSTINE; CISPLATIN; CYCLOHEXIMIDE; DACTINOMYCIN; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER RADIOTHERAPY; CANCER RESISTANCE; CONTROLLED STUDY; DNA TRANSFECTION; DRUG RESISTANCE; GENE TRANSFER; GLIOMA CELL; HUMAN; HUMAN CELL; IRRADIATION; MALIGNANT TRANSFORMATION; PRIORITY JOURNAL; PROTO ONCOGENE;

EID: 0029010631     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI117965     Document Type: Article

References (61)

1. Trauth, B. C., C. Klas, A. M. J. Peters, S. Matzku, P. Möller, W. Falk, K. M. Debatin, and P. H. Krammer. 1989. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science (Wash. DC). 245:301-305.
2. Yonehara, S., A. Ishii, and M. Yonehara. 1989. A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J. Exp. Med. 169:1747-1756.
3. Itoh, N., S. Yonehara, A. Ishii, M. Yonehara, S. I. Mizushima, M. Sameshima, A. Hase, Y. Seto, and S. Nagata. 1991. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell. 66:233-243.
4. Oehm, A., I. Behrmann, W. Falk, M. Pawlita, G. Maier, C. Klas, M. Li-Wever, S. Richards, J. Dhein, B. C. Trauth, H. Ponstingl, and P. H. Krammer. 1992. Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. Sequence identity with the Fas antigen. J. Biol. Chem. 267:10709-10715.
5. Suda, T., T. Takahashi, P. Golstein, and S. Nagata. 1993. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell. 75:1169-1178.
6. Weller, M., K. Frei, P. Groscurth, P. H. Krammer, Y. Yonekawa, and A. Fontana. 1994. Anti-Fas/APO-1 antibody-mediated apoptosis of cultured human malignant glioma cells. Induction and modulation of sensitivity by cylokines. J. Clin. Invest. 94:954-964.
7. Wong, G. H. W., and D. V. Goeddel. 1994. Fas antigen and p55 TNF receptor signal apoptosis through distinct pathways. J. Immunol. 152:1751-1755.
8. Owen-Schaub, L. B., R. Radinsky, E. Kruzel, K. Berry, and S. Yonehara. 1994. Anti-Fas on nonhematopoietic tumors: levels of Fas/APO-1 and bcl-2 are not predictive of biological response. Cancer Res. 54:1580-1586.
9. Reed, J. C. 1994. Bcl-2 and the regulation of programmed cell death. J. Cell Biol. 124:1-6.
10. Nuñez, G., L. London, D. Hockenbery, M. Alexander, J. P. McKearn, and S. J. Korsmeyer. 1990. Deregulated bcl-2 gene expression selectively prolongs survival of growth factor-deprived hemopoietic cell lines. J. Immunol. 144:3602-3610.
11. Sentman, C. L., J. R. Shutter, D. Hockenbery, O. Kanagawa, and S. J. Korsmeyer. 1991. bcl-2 inhibits multiple forms of apoptosis but not negative selection in thymocytes. Cell. 67:879-888.
12. Strasser, A., A. W. Harris, and S. Cory. 1991. bcl-2 transgene inhibits T cell death and perturbs thymic self-censorship. Cell. 67:889-899.
13. Collins, M. K. L., J. Marvel, P. Malde, and A. Lopez-Rivas. 1992. Interleukin 3 protects murine bone marrow cells from apoptosis induced by DNA damaging agents. J. Exp. Med. 176:1043-1051.
14. Epperly, M. W., M. A. Santucci, J. C. Reed, D. Shields, A. Halloran, and J. S. Greenberger. 1994. Expression of the human Bcl-2 transgene increases the radiation resistance of a hematopoielic progenitor cell line. Rad. Oncol. Invest. 2:77-83.
15. Griffiths, S. D., D. T. Goodhead, S. J. Marsden, E. G. Wright, S. Krajewski, J. C. Reed, S. J. Korsmeyer, and M. Greaves. 1994. Interleukin 7-dependent B lymphocyte precursor cells are ultrasensitive to apoptosis. J. Exp. Med. 179:1789-1797.
16. Miyashita, T., and J. C. Reed. 1992. Bcl-2 gene transfer increases relative resistance of S49.1 and WEHI7.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs. Cancer Res. 52:5407-5411.
17. Miyashita, T., and J. C. Reed. 1993. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood. 81:151-157.
18. Fisher, T. C., A. E. Milner, C. D. Gregory, A. L. Jackman, G. W. Aherne, J. A. Hartley, C. Dive, and J. A. Hickman. 1993. Bcl-2 modulation of apoptosis induced by anticancer drugs: resistance to thymidilate stress is independent of classical resistance pathways. Cancer Res. 53:3321-3326.
19. Hanada, M., S. Krajewski, S. Tanaka, D. Cazals-Hatem, B. A. Spengler, R. A. Ross, J. L. Biedler, and J. C. Reed. 1993. Regulation of Bcl-2 oncoprotein levels with differentiation of human neuroblastoma cells. Cancer Res. 53:4978-4986.
20. Kamesaki, S., H. Kamesaki, T. J. Jorgensen, A. Tanizawa, Y. Pommier, and J. Cossman. 1993. bcl-2 protein inhibits etoposide-induced apoptosis through its effects on events subsequent to topoisomerase II-induced DNA strand breaks and their repair. Cancer Res. 53:4251-4256.
21. Walton, M. I., D. Whysong, P. M. O'Connor, D. Hockenbery, S. J. Korsmeyer, and K. W. Kohn. 1993. Constitutive expression of human bcl-2 modulates nitrogen mustard and camptothecin induced apoptosis. Cancer Res. 53:1853-1851.
22. McDonnell, T. J., P. Troncoso, S. M. Brisbay, C. Logothetis, L. W. K. Chung, J.-T. Hsieh, S.-M. Tu, and M. L. Campbell. 1992. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res. 52:6940-6944.
23. Castle, V. P., K. P. Heidelberger, J. Bromberg, X. Ou, M. Dole, and G. Nuñez. 1993. Expression of the apoptosis-suppressing protein bcl-2, in neuroblastoma is associated with unfavorable histology and N-myc amplification. Am. J. Pathol. 143:1543-1550.
24. Hockenbery, D. M., M. Zutter, W. Hickey, M. Nahm, and S. J. Korsmeyer. 1991. BCL2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc. Natl. Acad. Sci. USA. 88:6961-6965.
25. Merry, D. E., D. J. Veis, W. F. Hickey, and S. J. Korsmeyer. 1994. bcl-2 protein expression is widespread in the developing nervous system and retained in the adult PNS. Development. 120:301-311.
26. Reed, J. C., L. Meister, S. Tanaka, M. Cuddy, S. Yum, C. Geyer, and D. Pleasure. 1991. Differential expression of bcl2 protooncogene in neuroblastoma and other human tumor cell lines of neural origin. Cancer Res. 51:6529-6538.
27. 2 induces apoptosis of murine T cell clones without downregulating bcl-2 mRNA expression. Eur. J. Immunol. 24:1293-1300.
28. Frei, K., D. Piani, U. V. Malipiero, E. Van Meir, N. de Tribolet, and A. Fontana. 1992. Granulocyte-macrophage colony-stimulating factor (GM-CSF) production by glioblastoma cells. Despite the presence of inducing signals GM-CSF is not expressed in vivo. J. Immunol. 148:3140-3146.
29. Frei, K., C. Siepl, P. Groscurth, S. Bodmer, C. Schwerdel, and A. Fontana. 1987. Antigen presentation and tumor cytotoxicity by interferon-γ-treated microglial cells. Eur. J. Immunol. 17:1271-1278.
30. Aiello, A., D. Delia, M. G. Borrello, D. Biassoni, R. Giardini, E. Fontanella, F. Pezzella, K. Pulford, M. Pierotti, and G. Della Porta. 1992. Flow cytometric detection of the mitochondrial BCL-2 protein in normal and neoplastic human lymphoid cells. Cytometry. 13:502-509.
31. Karasuyama, H., and F. Melchers. 1988. Establishment of mouse cell lines which constitutively secrete large quantities of interleukin 2, 3, 4 or 5, using modified cDNA expression vectors. Eur. J. Immunol. 18:97-104.
32. Deng, G., and E. R. Podack. 1993. Suppression of apoptosis in a cytotoxic T-cell line by interleukin 2-mediated gene transcription and deregulated expression of the protooncogene bcl-2. Proc. Natl. Acad. Sci. USA. 90:2189-2193.
33. Miyashita, T., S. Krajewski, M. Krajewska, H. G. Wang, H. K. Lin, D. A. Lieberman, B. Hoffman, and J. C. Reed. 1994. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene. 9:1799-1805.
34. Marvel, J., G. R. Perkins, A. Lopez Rivas, and M. K. L. Collins. 1994. Growth factor starvation of bcl-2 overexpressing murine bone marrow cells induced refractoriness to IL-3 stimulation of proliferation. Oncogene. 9:1117-1122.
35. Kitada, S., S. Takayama, K. DeRiel, S. Tanaka, and J. C. Reed. 1994. Reversal of chemoresistance of lymphoma cells by antisense-mediated reduction of bcl-2 gene expression. Antisense Res. Dev. 4:71-79.
36. Hennet, T., G. Bertoni, C. Richter, and E. Peterhans. 1993. Expression of BCL-2 protein enhances the survival of mouse fibrosarcoid cells in tumor necrosis factor-mediated cytotoxicity. Cancer Res. 53:1456-1460.
37. Itoh, N., Y. Tsujimoto, and S. Nagata. 1993. Effect of bcl-2 on Fas antigen-mediated cell death. J. Immunol. 151:621-627.
38. Vanhaesebroeck, B., J. C. Reed, D. De Valck, J. Grooten, T. Miyashita, S. Tanaka, R. Beyaert, F. Van Roy, and W. Fiers. 1993. Effect of bcl-2 protooncogene expression on cellular sensitivity to tumor necrosis factor-mediated cytotoxicity. Oncogene. 8:1075-1081.
39. Taghian, A., J. Ramsay, J. Allalunis-Turner, W. Budach, D. Gioioso, F. Pardo, P. Okunieff, N. Bleehen, R. Urtasun, and H. Suit. 1993. Intrinsic radiation sensitivity may not be the major determinant of the poor clinical outcome of glioblastoma multiforme. Int. J. Radiation Oncology Biol. Phys. 25:243-249.
40. Owen-Schaub, L. B., S. Yonehara, W. L. Crump III, and E. A. Grimm. 1992. DNA fragmentation and cell death is selectively triggered in activated human lymphocytes by Fas antigen engagement. Cell. Immunol. 140:197-205.
41. Rouvier, E., M. L. Luciani, and P. Golstein. 1993. Fas involvement in Ca2+-independent T cell-mediated cytotoxicity. J. Exp. Med. 177:195-200.
42. Vignaux, F., and P. Golstein, 1994. Fas-based lymphocyte-mediated cytotoxicity against syngeneic activated lymphocytes: a regulatory pathway? Eur. J. Immunol. 24:923-927.
43. Kägi. D., F. Vignaux, B. Ledermann, K. Bürki, V. Depraetere, S. Nagata, H. Hengartner, and P. Golstein. 1994. Fas and perform pathways as major mechanisms of T cell-mediated cytotoxicity. Science (Wash. DC). 265:528-530.
44. Leithäuser, F., J. Dhein, G. Mechtersheimer, K. Koretz, S. Brüderlein, C. Henne, A. Schmidt, K. M. Debatin, P. H. Kramtner, and P. Möller. 1993. Constitutive and induced expression of APO-1, a new member of the nerve growth factor/ tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab. Invest. 69:415-429.
45. Vaux, D. L., H. L. Aguila, and I. L. Weissman. 1992. Bcl-2 prevents death of factor-deprived cells but fails to prevent apoptosis in targets of cell mediated killing. Int. Immunol. 4:821-824.
46. Torigoe, T., J. A. Millan, S. Takayama, R. Taichman, T. Miyashita, and J. C. Reed. 1994. Bcl-2 inhibits T-cell-mediated cytolysis of a leukemia cell line. Cancer Res. 54:4851-4854.
47. Iwai, K., T. Miyawaki, T. Takizawa, A. Konno, K. Ohta, A. Yachie, H. Seki, and N. Taniguchi. 1994. Differential expression of bcl-2 and susceptibility to anti-Fas-mediated cell death in peripheral blood lymphocytes, monocytes, and neutrophils. Blood. 84:1201-1208.
48. Mapara, M. Y., R. Bargou, C. Zugck, H. Döhner, F. Ustaoglu, R. R. Jonker, P. H. Krammer, and B. Dörken. 1993. APO-1 mediated apoptosis or proliferation in human chronic B lymphocytic leukemia: correlation with bcl-2 oncogene expression. Eur. J. Immunol. 23:702-708.
49. Kondo, E., T. Yoshino, I. Yamadori, Y. Matsuo, N. Kawasaki, J. Minowada, and T. Akagi. 1994. Expression of Bcl-2 protein and Fas antigen in non-Hodgkin's lymphomas. Am. J. Pathol. 145:330-337.
50. Salmon, M., D. Pilling, N. J. Borthwick, N. Viner, G. Janossy, P. A. Bacon, and A. N. Akbar. 1994. The progressive differentiation of primed T cells is associated with an increasing susceptibility to apoptosis. Eur. J. Immunol. 24:892-899.
51. Hockenbery, D. M., Z. N. Oltvai, X. M. Yin, C. L. Milliman, and S. J. Korsmeyer. 1993. Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell. 75:241-251.
52. Hug, H., M. Enari, and S. Nagata. 1994. No requirement of reactive oxygen intermediates in Fas-mediated apoptosis. FEBS (Fed. Eur. Biochem. Soc.) Lett. 351:311-313.
53. Schulze-Osthoff, K., P. H. Krammer, and W. Dröge. 1994. Divergent signalling via APO-1/Fas and the TNF receptor, two homologous molecules involved in physiological cell death. EMBO (Eur. Mol. Biol. Organ.) J. 13:4587-4596.
54. Cifone, M. G., R. De Maria, P. Roncaioli, M. R. Rippo, M. Azuma, L. L. Lanier, A. Santoni, and R. Testi. 1994. Apoptotic signaling through CD95 (Fas/ Apo-1) activates an acidic sphingomyelinase. J. Exp. Med. 177:1547-1552.
55. Richardson, B. C., N. D. Lalwani, K. J. Johnson, and R. M. Marks. 1994. Fas ligation triggers apoptosis in macrophages but not endothelial cells. Eur. J. Immunol. 24:2640-2645.
56. Miescher, S., T. L. Whiteside, N. De Tribolet, and V. Von Fliedner. 1988. In situ characterization, clonogenic potential, and antitumor cytolytic activity of T lymphocytes infiltrating human brain cancers. J. Neurosurg. 68:438-448.
57. Fontana, A., H. Hengartner, N. de Tribolet, and E. Weber. 1984. Glioblastoma cells release interleukin 1 and factors inhibiting interleukin 2-mediated effects. J. Immunol. 132:1837-1844.
58. Wrann, M., S. Bodmer, R. De Martin, C. Siepl, R. Hofer-Warbinek, K. Frei, E. Hofer, and A. Fontana. 1987. T cell suppressor factor from human glioblastoma cells is a 12.5-kd protein closely related to transforming growth factor-β. EMBO (Eur. Mol. Biol. Organ.) J. 6:1633-1636.
59. De Martin, R., B. Haendler, R. Hofer-Warbinek, H. Gaugitsch, M. Wrann, H. Schlüsener, J. M. Seifert, S. Bodmer, A. Fontana, and E. Hofer. 1987. Complementary DNA for human glioblastoma-derived T cell suppressor factor, a novel member of the transforming growth factor-β gene family. EMBO (Eur. Mol. Biol. Organ.) J. 6:3673-3677.
60. Yoshida, J., T. Wakabayashi, M. Mizuno, K. Sugita, T. Yoshida, S. Hori, T. Mori, T. Sato, A. Karashima, K. Kurisu, K. Kiya, and T. Uozumi. 1992. Clinical effect of intra-arterial tumor necrosis factor-α for malignant glioma. J. Neurosurg. 77:78-83.
61. Farkkila, M., J. Jääskeläinen, M. Kallio, G. Blomstedt, R. Raininko, P. Virkkunen, A. Paetau, H. Sarelin, and M. Mäntyla. 1994. Randomised, controlled study of intratumoral recombinant γ-interferon treatment in newly diagnosed glioblastoma. Br. J. Cancer. 70:138-141.